DiscoveryProbe™ FDA-approved Drug Library: High-Content Screening for Drug Repositioning

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) comprises 2,320 clinically approved bioactive compounds designed for high-throughput and high-content screening workflows [product]. Each compound is pre-dissolved at 10 mM in DMSO and provided in formats compatible with automation and long-term storage. The library supports rapid drug repositioning by enabling the identification of new pharmacological targets and mechanisms of action, as evidenced by peer-reviewed studies using FDA-approved compound collections to discover covalent binders of SARS-CoV-2 main protease (Andi et al., 2022). Mechanistic diversity includes receptor agonists/antagonists, enzyme inhibitors, and signal pathway regulators. The library's application is validated in oncology, neurodegenerative disease research, and infectious disease target screening, with standardized workflows minimizing technical variability [internal].

Biological Rationale

Drug repositioning leverages clinically approved compounds to identify new therapeutic uses, reducing the time and cost of drug development (Andi et al., 2022). Existing drugs have well-characterized safety, pharmacokinetics, and pharmacodynamics. Screening libraries of FDA-approved compounds, such as DiscoveryProbe™, enables systematic evaluation of repurposing potential in disease models. FDA, EMA, HMA, CFDA, and PMDA approvals ensure broad regulatory coverage and clinical relevance. Compounds target diverse mechanisms: receptor modulation, enzyme inhibition, ion channel regulation, and signaling pathway disruption. High-throughput screening (HTS) of such libraries has identified novel inhibitors for viral proteases, kinases, and neurodegenerative disease enzymes. This approach accelerates translation from bench to clinical application [internal].

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The DiscoveryProbe™ FDA-approved Drug Library contains compounds with diverse and well-defined mechanisms of action. Representative drugs include:

• Doxorubicin: Topoisomerase II inhibitor inducing DNA damage and apoptosis in cancer cells.
• Metformin: AMPK activator and mitochondrial complex I inhibitor used in metabolic disease and cancer research.
• Atorvastatin: HMG-CoA reductase inhibitor, modulating cholesterol biosynthesis and vascular inflammation.

Other compound classes include serotonin receptor agonists, GABA antagonists, protein kinase inhibitors, and ion channel modulators. The library enables screening for compounds acting as:

• Receptor agonists/antagonists (e.g., GPCRs, nuclear receptors).
• Enzyme inhibitors (e.g., proteases, kinases, phosphatases).
• Ion channel modulators (e.g., sodium, potassium, calcium channels).
• Signal pathway regulators (e.g., MAPK, PI3K/AKT, Wnt).

This mechanistic diversity facilitates identification of drugs with novel activities in cell-based or biochemical assays, particularly in high-content screening platforms [internal].

Evidence & Benchmarks

• FDA-approved drug libraries have enabled direct identification of covalent inhibitors of SARS-CoV-2 main protease (M_pro) in crystallographic and binding assays (Andi et al., 2022, DOI).
• Remdesivir, originally developed for hepatitis C and Ebola, was rapidly repurposed and clinically approved for COVID-19 by screening existing antiviral compounds (Andi et al., 2022, DOI).
• High-throughput screening of FDA-approved libraries identified Tideglusib as a novel Pif1 helicase inhibitor, illustrating translational potential for neurodegenerative disease targets (internal).
• Libraries such as DiscoveryProbe™ are used in oncology and neuroepigenetics for target validation and repositioning, leading to new clinical trials for cancer and neurological disorders (internal).
• Compounds provided as 10 mM DMSO solutions remain stable for ≥12 months at -20°C and ≥24 months at -80°C, supporting reproducible screening workflows (product).

Applications, Limits & Misconceptions

DiscoveryProbe™ FDA-approved Drug Library supports a wide range of research applications:

• High-throughput screening (HTS) of oncology, infectious disease, and neurodegeneration models.
• Drug repositioning studies to identify new indications for existing therapeutics.
• Pharmacological target identification and validation using well-characterized clinical compounds.
• Screening for enzyme inhibitors, receptor modulators, and pathway regulators.

Limits and misconceptions include:

Common Pitfalls or Misconceptions

• Not all hits are clinically translatable: New activities detected in vitro may not translate to in vivo efficacy or safety.
• Concentration-dependent artifacts: Screening at high concentrations (≥10 µM) can yield off-target or non-specific effects.
• Lack of proprietary or preclinical compounds: The library does not include investigational or experimental agents not yet approved by major regulatory agencies.
• Solvent compatibility: DMSO sensitivity in some biological assays may require further dilution or controls.
• Limited to known clinical entities: Novel chemical scaffolds outside approved pharmacopeias are not represented.

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library is pre-dissolved at 10 mM in DMSO and shipped in 96-well microplates, deep well plates, or 2D barcoded screw-top tubes. Compounds are stable for 12 months at -20°C and 24 months at -80°C. The library is compatible with automated liquid handling and high-throughput screening platforms. Recommended screening concentrations typically range from 1–10 µM in biochemical or cell-based assays, with appropriate DMSO controls. Shipping is performed on blue ice for evaluation samples and at room temperature or on blue ice for larger sizes, ensuring compound integrity. The ready-to-screen format minimizes preparation errors and supports reproducible, large-scale screens [internal]. For further benchmarking, see the detailed product documentation at DiscoveryProbe™ FDA-approved Drug Library.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library empowers researchers to accelerate drug repositioning, target identification, and mechanistic discovery [internal]. Its clinically vetted diversity, pre-dissolved convenience, and compatibility with high-throughput and high-content workflows set a new standard for pharmacological innovation. Recent peer-reviewed studies underscore the utility of FDA-approved compound libraries in rapid response to emerging infectious diseases and in the identification of new therapeutic targets (Andi et al., 2022). While the library is limited to approved clinical entities, it remains a cornerstone for translational research across disease areas. For advanced strategies in integrating compound libraries with structural biology and pathway analysis, see related analyses here, which this article extends by detailing practical workflow integration and benchmarking.